Lilly’s Anti SARS CoV-2, bamlanivimab

 

Lilly’s monoclonal antibody for early treatment of the CCP virus was just approved by the FDA, soon to be followed by Repligen’s product, the one that President Trump received. Administration of the concentrated convalescent plasma like serum IV in early infected persons who are in the highly contagious period, will require an isolation area and protective suits for those administrating the intravenous cocktail. Logistics, initial scarcity and priority of distribution will also be a challenge. 

 

President Trump promised mass production and free military distribution. This availability has to be free but prioritized. It cannot become political. One political globalist has already suggested that we share with the world before distribution at home.

 

Herein our suggested priority would start with the military in contested areas and critical care workers. The military as promised could deliver to clinical facilities in towns with the highest burden of spread, hot zones, initially limiting treatment to citizens over 60 with coexisting conditions within the suggested 4 to 5 days of symptom-onset and positive PCR. As availability increases, legal guests in the US should be included and only with a decrease in cases and increased availability of serum, extend qualification to younger persons without concern for legal status. Crowded nursing homes, prisons and new hotspots might get special attention when the spread of COVID19 goes out of control. There may be tension over priorities because most drug companies are multinational. 

 

This strategy puts national security first considering the the threats in the Middle East and South Pacific and then to the most vulnerable. Some might argue against putting our military and at-risk persons and citizens first, but I would argue that we don’t have the strength to help others unless we see to our own vulnerabilities and safety.